Tag: CATB

Blue Horseshoe Stocks: KOOL, TIF Recaps & More

Endocyte, Inc. ECYT

We initially took notice of ECYT on Monday morning just as the company announced it had completed a worldwide license for its prostate cancer treatment now moving into Phase-3 development.

The stock made a solid 130% rip from 1.63 to 3.75 that morning, but it was only just getting started. Yesterday morning the stock ran hard once again, reaching its peak at a new annual high of 6.55. That puts the total on our two-day observed increased of 302% while volume over the same period has been literally hundreds of times greater than the monthly average prior to Monday’s bombshell PR.

Tiffany & Co. TIF – Options Update

As we were just mentioning yesterday morning, we’ve been tracking the TIF 10/20 $92-93 Calls since the morning of September 28th. TIF stock has maintained its gradual ascent since that time, and with that, we’ve seen the potential gains made off of our ideas grow along with it.

The following ranges represent the lows from the 28th to the highs achieved during yesterday’s session:

$92 Calls – Range: 1.00-2.20 – Max Gain: 120%
$92.50 Calls – Range: .85-2.19  – Max Gain: 158%.
$93 Calls – Range: .83-2.15 – Max Gain: 159%

Cesca Therapeutics Inc. KOOL

After including KOOL in yesterday morning’s watchlist, we watched as the stock made a very nice intraday run on the chart with the help of some positive news.

The U.S. Patent and Trademark Office issued a Notice of Allowance on the company’s patent application for its proprietary method for separating target cells from blood, marrow, and other sources.

That prompted a solid boost from 3.96 to 6.44 on the day, marking an intraday push of 63% which was accompanied by the trading of 223X more shares than the monthly average!

Extended Watchlist:
CATB, RGSE, CAPR, ATNM, VKTX, MNKD, BIOP,  HTBX

Blue Horseshoe Stocks: ECYT Recap & More

Endocyte, Inc. ECYT

We took notice of ECYT yesterday morning during our routine premarket scan, and due to some abnormal activity, we decided to include it in the daily watchlist.

It turned out to be a splendid idea, with the stock ultimately recording a hugely bullish session. ECYT traded from its low of 1.63 just following the open, to its high of 3.75 just prior to the close. It worked out to a single-session rip of 130% and it came on over 180X the monthly average volume. The stock has also hit a new high of 6.07 in the premarket this morning, pushing our observed move in less than 24 hours to a whopping 272%

It was especially impressive because of the timing, which couldn’t have been any better. Prior to yesterday’s session the stock was stagnating for several months. The move was catalyzed primarily by the announcement of the completion of a worldwide license on the company’s prostate cancer treatment, which will be moving on to Phase III development. (>>View PR)

Rigel Pharmaceuticals, Inc. RIGL

Speaking of solidly-timed calls on pharma plays, we also caught RIGL and included it in yesterday’s premarket report. It didn’t see the type of move that the previously mentioned stock, but got off to a respectable start.

RIGL traded in a range from 2.85-3.42, a modest rise of 20%, but did so on nearly 17X the monthly average volume, and closed near its high of day. We’ll continue to observe this play to see if it can establish a sustained uptrend.

Capricor Therapeutics, Inc. CAPR

We were just updating our readers yesterday morning on the moves CAPR had made since we had alerted it onSeptember 20th from its low of 1.80.

What followed was another nice session for the stock, which ran to a new high of 4.25; a total increase of 136% in a span of just eight trading days.


Tiffany & Co. TIF – Options Update

We also want to quickly update readers on our TIF options ideas that we submitted on the morning of September 28th, the TIF 10/20 $92-93 Calls. The stock has been in a continuous bullish pattern since then, and those calls made some pretty nice gains in the process.

$92 Calls – Range: 1.00-2.13 – Max Gain: 113%
$92.50 Calls – Range: .85-1.74  – Max Gain: 105%.
$93 Calls – Range: .83-1.88 – Max Gain: 127%

Extended Watchlist:
ETRM, VICL, DMPI, TA, KOOL, CATB

Blue Horseshoe Stocks: INMG, DRNK Recaps & More

Innovativ Media Group, Inc. INMG

When we last left off with INMG on Thursday morning, we had already seen a five session swing of 1400% over the previous week. While we certainly acknowledged the impressive gains, we stated, “the stock will peel back off of these impressive highs and that’s when we’ll be looking for what could be a serious dip-and-rip pattern.” Our assessment of the situation turned out to be very astute, and INMG experienced exactly the activity we suggested.

That morning, the stock dipped down significantly to ultimately find support at .0145, from which point it began a three-session span of recording higher lows and higher highs, leading up to yesterday’s high of .032.  The ‘rip’ in our observed dip-and-rip on INMG has thus far amounted to an added opportunity for gains of up to 121% on the upswing!

NoHo, Inc. DRNK

Continuing along with another fantastic call we made just yesterday, we’ve got DRNK, which we explicitly stated could be the next super-subpenny “to go for a big ride”. It took no time at all for our hunch to come to fruition, as it showed us a really nice move on day one.

The stock traded up from .0003 to .00051, for a 70% intraday pop, which came on more than eight times the monthly average volume with more than 800 million shares changing hands on the day. It also held half its advance into a .0004 close.

The move was helped along by a well-received PR which hit wires shortly after our morning report concerning the company’s declaration of a moratorium on conversions along with the negotiation of a debt buyout:

David Mersky, NOHO’s CEO, stated, “We have come to terms with our majority note holder to freeze conversions, which puts NOHO in a very strong position moving forward with significant developments underway. This is a strong signal of our majority debt holder’s confidence in the long term vision we have for the Company. This agreement is also a big win for our shareholders, as we continue to make changes to reduce the outstanding shares and avoid dilution as a priority moving forward.” (>>View Full PR)

We’re really going to want to keep an eye on DRNK. With a commitment to cleaning up their share structure, along with the added attention that a big move on the chart is going to bring, we won’t rule out the possibility of DRNK breaking from the super-subpenny range to the subpenny range, or even higher.

Extended Watchlist:
PTN, ERHE, WNTR, CANF, CATB, CAPR, NAVB, STRP